Sterling Capital Management’s Benitec Biopharma BNTC Stock Holding History
Bought
Maintained
Sold
Other funds holding BNTC
IAM
Sterling Capital Management's BNTC Position: Q3 2026 in Review
Sterling Capital Management increased its Benitec Biopharma (BNTC) stake by 6.8% in Q3 2026, buying an estimated $342 and bringing the position to 437 shares worth $4.37K. The position accounts for ﹤0.01% of the portfolio, ranked #2924.
Sterling Capital Management first reported a position in BNTC in Q2 2025 and has held it in 6 quarters since. The position peaked at $5.47K in Q2 2026. 91 funds tracked by Wall St. Rank hold BNTC as of Q3 2026.
- Sterling Capital Management held 437 shares of Benitec Biopharma worth $4.37K as of Q3 2026.
- Sterling Capital Management bought 28 Benitec Biopharma shares in Q3 2026, an estimated $342.
- Benitec Biopharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2924 holding.
- Sterling Capital Management first reported a position in Benitec Biopharma in Q2 2025 and has held it in 6 quarters since.
- Sterling Capital Management's Benitec Biopharma position peaked at $5.47K in Q2 2026.
- 91 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.